Professor Kenneth Willeford, BSc, PhD
Professor Willeford is a Professor of Biochemistry and Molecular Biology at Mississippi State University where he has undertaken extensive research into the effects of using the platform Caprine derived technology in the treatment of animals. As a result, he is largely responsible for the discovery of SF-1019. And, while it is recognized that a substantial series of scientific studies and human clinical trials still have to be addressed, a large number of animal studies relating to the use of SF1019, using various models, have been undertaken and published by Professor Willeford during the past seven years. These studies include a series of successful field trials in the treatment of Canine Parvo virus and Equine West Nile Virus.
Professor Angus Dalgleish, MBBS, BSc, MD, FRCP, RACP, FRCPath, FMedSci
Professor Dalgleish is the Foundation Professor of Oncology at St. George’s University of London, formerly St. George’s Hospital Medical School. He trained at University College London where he performed an intercalated BSc with Professor J. Z. Young, FRS. After house jobs in London and Poole he spent a year in the flying doctor service in Australia. He then joined an internal medicine programme in Brisbane before focusing on radiotherapy and oncology. After obtaining his Fellowship Professor Dalgleish became a Clinical Research Fellow to Professor Robin Weiss, FRS, at the Institute of Cancer Research at the Royal Marsden Hospital. There he developed an interest in retroviruses as causative agents of human disease and the role of the immune response in the pathogenesis of these diseases.
Professor Dalgleish is a co-discoverer of the CD4 receptor for HIV and has published many important papers on AIDS and HIV. More recently he has become very interested in the role of the immune response and the treatment of cancer and has focused on cell based vaccines in particular. He founded Onyvax, a start up Biotech Company, at St. George’s in 1998, with the focus of developing a cell based vaccine for prostate cancer. Professor Dalgleish’s main current research interest is the use of sequential managed immunotherapy to optimize the currently available approaches. Current studies are aimed at increasing the efficacy of dendritic cell vaccines through the use of toll-like receptor agonists, T-regulatory cell reduction and expansion of effector cells.
Professor Jonathon Heeney, BSC, DVM (Honours), DVSc (Pathology), PhD, MRCVS
In addition to his work at Argyll, and as a Professor of Veterinary Science at Cambridge University (UK), and as a member of the Eurovac Board and scientific board of the Cancer Vaccine Institute; Professor Heeney is a former Professor at the Biomedical Primate Research Centre and head of the Department of Virology. He has a proven track record of management and participation in large EU projects. His multidiscipline research team, consisting of highly qualified young men and women, has been responsible for the planning, immunological and virological assessment of pre-clinical HIV vaccine trials in non-human primates for more than ten years. Professor Heeney has made a number of key contributions to AIDS vaccine development, including defining the central role of T-helper responses in vaccine induced immunity in demonstrating viral vaccine protection from cell-associated challenges and the role of chemokine responses in protective immunity. His team has further advanced the pragmatic pre-clinical evaluation of HIV-I vaccine candidates in non-human primates for selection and refinement for clinical trials. Professor Heeney is the founder of an international series of meetings on correlates of protective immunity to HIV/AIDS.
David Maizels, MD, MSc, MRCS, LRCP
Dr. Maizels has extensive knowledge of Caprine derived serum and is the lead clinician of the SF-1019 project. He studied medicine at Kings College University Hospital in London, qualifying as a medical doctor in 1974. In addition to his private practice which commenced in 1982; he has been a UK registered NHS general medical practitioner since 1976 providing a wide range of general medical services within the National Health Service.
Dr. Maizels also holds an MSc in Nutritional Medicine and is a qualified acupuncturist.
Mr. Anthony Haines
Mr. Haines is an experienced development engineer, management consultant and business manager with more than 25 years of experience in the development of new businesses and technologies and the administration and management of complex product development and commercialization. In that capacity, he serves as resident manager and administrator for Argyll Biotechnologies’ United Kingdom and European operations.
Mr. Stanley D. T. White, BSc
Mr. White received a degree in Agriculture from the University of Wisconsin in 1979. He has experience teaching and managing educational farms and has managed an educational farm for the University of Rhode Island and a non-profit farm near Boston. While managing the non-profit farm just outside of Boston, Mr. White introduced a program of raising endangered livestock breeds as a “for profit” model. Some of the breeds collected were extinct in their native England or continental Europe. The farm received both regional and national recognition for its work in genetic conservation.
In 1994, Mr. White incorporated Capralogics, Inc., a licensed animal research facility that specializes in the production of antibodies and serum proteins from rabbits, goats and sheep. Both he and his company have been working on the production of raw materials and the manufacturing processes of SF-1019 since its inception.
